Plain-English translation of NCT07584499 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is a Phase I trial testing a new medicine called in children with relapsed or hard-to-treat solid tumors that have a specific protein marker called EGFR. The medication is an antibody-drug conjugate, which means it's designed to find and attack cancer cells while sparing healthy cells. Early adult studies showed promise with manageable side effects, and now researchers want to see if it works safely in children.
Children with cancers that come back after treatment or don't respond to standard chemotherapy have very few good options, and existing treatments can cause serious side effects. This new medication targets a protein found on many pediatric cancers, offering a potentially more focused approach than traditional chemotherapy.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an intravenous infusion (through a vein) over 30 minutes to 3 hours, once every 3 weeks for up to 24 weeks (8 treatment cycles). The study starts by testing lower doses and gradually increases them to find the safest effective dose. Throughout the trial, you'll have blood tests, scans, and check-ins with the study team to monitor how you're doing and whether the medication is working.
AI-generated summary from trial data · Jun 10, 2026 · Not medical advice
China